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Pulmonary arterial hypertension is a chronic, progressive disease characterized by elevation of
pulmonary artery pressure and pulmonary vascular resistance that ultimately results in right
ventricular failure and death. Multiple mechanisms are involved in the pathogenesis of pulmo-
nary arterial hypertension, including prostacyclin, endothelin-1, and nitric oxide pathways
amongst others. The first agent to be approved for the treatment of pulmonary arterial hyper-
tension was synthetic prostacyclin (epoprostenol), followed by prostaglandin analogs (iloprost,
treprostinil, and beraprost [Japan and Korea]), which act on prostaglandin receptors. This
article reviews the physiology and pathophysiology of prostanoids, summarizes key clinical
studies of prostaglandin analogs for the treatment of pulmonary arterial hypertension, and
discusses important pharmacokinetic and pharmacodynamic distinctions between the various
prostaglandin analogs. Different prostaglandin analogs have disparate binding affinities for
the various prostaglandin receptors and different G-protein-coupled receptor interactions,
which may result in varying clinical efficacy and safety depending on the target tissue. Differ-
ences in formulation, route of administration, effectiveness, and safety may all play a role in
deciding which prostaglandin analog to prescribe for an individual patient. Head-to-head
studies will be needed to confirm differences in efficacy and safety for the various prosta-
glandin analogs.
ª 2009 Elsevier Ltd. All rights reserved.392 0821.
9 Elsevier Ltd. All rights reserved.
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Pulmonary arterial hypertension (PAH) is a chronic,
progressive disease characterized by elevation of pulmonary
artery pressure (PAP) and pulmonary vascular resistance
(PVR), which ultimately results in right ventricular failure
and death.1 The histopathology of PAH involves changes in
both the pulmonary vasculature and the right ventricle that
include vasoconstriction, remodeling, and thrombosis in situ.
Pulmonary arterial hypertension is an incurable disease that
is associated with a poor prognosis. In a National Institutes of
Health (NIH) sponsored registry including 194 patients with
PAH in the 1980s, the estimated median survival was 2.8
years (95% confidence interval [CI], 1.9e3.7 years) and the 1-
year survival rate was 68% (95% CI, 61e75%).2
Since the time of the original NIH registry and study,
treatment options have improved by targeting pathways
involved in the pathogenesis of PAH. Each approved therapy
with indications for PAH targets one of the following three
signaling pathways: prostacyclin, endothelin-1, or nitric
oxide.1 The first agent to be approved by the United States
Food and Drug Administration (FDA) for PAH was synthetic
prostacyclin (epoprostenol). Intravenous epoprostenol was
approved by the FDA in 1995, followed by subcutaneous tre-
prostinil in 2002, intravenous treprostinil in 2004, and inhaled
iloprost in 2004. Oral and inhaled formulations of treprostinil
and a sustained-release formulation of iloprost are currently
in development.3 A non-prostanoid prostacyclin receptor
agonist, NS-304/ACT-293987, is also being developed.4 The
second class of therapeutic agents developed for the treat-
ment of PAH are endothelin receptor antagonists (ERAs) and
include bosentan, ambrisentan, and sitaxsentan. The third
classofdrugs for the treatment ofPAHarephosphodiesterase-
5 (PDE5) inhibitors, which target the nitric oxide pathway andinclude sildenafil and tadalafil. Even as novel therapies that
target the endothelin receptor and nitric oxide pathways are
developed, prostaglandin-based therapies continue to be the
front-line therapy for functional class IV patients with PAH.5,6
Although early diagnosis (and lead-time bias) may have
contributed to better outcomes, these new treatment
options have been credited with improving the prognosis for
patients with PAH since the late 1980s, with current 1-year
survival rates ranging from 85% to 97%.7e11 The objectives of
this manuscript are to review the physiology and patho-
physiology of prostanoids, including immune effects, as well
as to review some of the clinical studies for the various
prostaglandin analogs for the treatment of PAH. This manu-
script reviews the prostaglandins that play a role in the
pulmonary circulation, including those approved for PAH and
those currently in clinical development. Since different
analogs may have heterogeneous affinities for the various
prostaglandin receptors, there may be differences in the
mechanisms of action of these prostaglandin analogs, espe-
cially since the route of administration may be different.Prostanoids and prostanoid receptors
Definitions
Eicosanoids are signaling molecules derived from twenty-
carbon essential fatty acids. Prostanoids are the naturally
occurring subclass of eicosanoids consisting of the prosta-
glandins and the thromboxanes. Prostanoids are arach-
idonic acid metabolites12 that can be classified into
prostaglandins (PG), which contain a cyclopentane ring,
and thromboxanes, which contain a cyclohexane ring. The
metabolism of arachidonic acid is shown in Fig. 1.
Figure 1 Biosynthesis of prostanoids. Arachidonic acid ismetabolized by cyclooxygenase (COX)-1 or -2 to the unstable endoperoxide
PGH2, the common precursor for the five principal prostaglandins. Thromboxane A2, PGD2, PGE2, PGI2, and PGF2a are generated by
individual prostaglandin synthase enzymes (TxAS, PGDS, PGES, PGIS, and PGFS) and elicit their biological effects by activating cell
surface G-protein-coupled receptors. NSAIDs, non-steroidal anti-inflammatory drugs; PGDS, prostaglandin D synthase; PGES, prosta-
glandin E synthase; PGIS, prostaglandin I synthase; PGFS, prostaglandin F synthase; TXA2, thromboxane A2. Reprinted from Pharmacol
Ther, 103(2), Hata AN and Breyer RM, Pharmacology and signaling of prostaglandin receptors: Multiple roles in inflammation and
immune modulation, 20, Copyright (2004), with permission from Elsevier.26
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into prostaglandin D (PGD), E (PGE), F (PGF), H (PGH), and I
(PGI, prostacyclin). The abbreviations are commonly fol-
lowed by an index (for instance PGE2), which indicates the
number of double bonds present in the various side chains
attached to the cyclopentane/cyclohexane ring. Prosta-
glandin analogs used clinically are listed in Table 1. A
summary of the physiological roles of various prostanoids in
major organ systems is shown in Table 2.
There are currently nine known prostanoid receptors on
various cell types, which are termed DP1e2, EP1e4, FD, IP, and
TP (Table 3). These are seven-transmembrane G-protein-
coupled receptors (GPCR) that are named for the prostanoids
that bind most readily to them; however, cross-binding affin-
ities are largely unknown. Prostanoid receptors can be grou-
ped into different categories, based on the type of
heterotrimeric G-protein activated by the different receptors,
and thus the cellular response evoked.12 The first category
consists of the relaxant receptors, IP, EP2, EP4, and DP, which,
in general, activate the G-protein Gs, which stimulates cyclic
adenosine monophosphate (cAMP) production by adenylatecyclase. The second category includes the contractile type of
prostanoid receptors, TP, EP1, and FP, which activate the G-
protein Gq, mediating enhanced intracellular Ca
2þ levels by
influencing phosphatidylinositol turnover.
The G-protein that is activated by a specific prostanoid
receptor may sometimes differ between cell types and may
depend upon ligand concentration. For instance, IP, which
normally activates Gs, is also capable of activating Gq if the
concentration of IP is high enough and has also been sug-
gested to couple to Gi in some cases.
13
Thromboxane and TP
ThromboxaneA2 (TXA2) hasmultiple actions oncardiovascular
function. It affects platelet shape and aggregation and
defective TP receptor signaling has been linked to bleeding
disorders.14 Increased thromboxane synthesis is associated
with acute myocardial ischemia15 and heart failure.16
Thromboxane A2 is also a potent bronchoconstrictor, stimu-
lating airway smoothmuscle cell proliferation and potentially
leading to asthma.17 In humans, the TP receptor exists as two
Table 1 Prostaglandin analogs used clinically.
Name Mechanism of action Physiologic use(s)
Alprostadil Prostaglandin E1 agonist Erectile dysfunction
a
Beraprost Prostacyclin agonist Arterial occlusive disorders, peripheral vascular disorders,
pulmonary hypertension, renal failure
Bimatoprost Prostaglandin F2 alpha agonist Glaucoma,
a ocular hypertensiona
Enprostil Prostaglandin E2 agonist Peptic ulcer
Iloprost Prostacyclin agonist Arterial occlusive disorders, Buerger’s disease, heart failure,
ischemic heart disorders, peripheral vascular disorders,
pulmonary arterial hypertension,a Raynaud’s disease
Latanoprost Prostaglandin F2 alpha agonist Glaucoma,
a ocular hypertensiona
Lubiprostone Chloride channel agonist Constipation,a irritable bowel syndromea
Misoprostol Prostaglandin E1 agonist Ulcer prevention
a
Travoprost Prostaglandin F2 alpha agonist Glaucoma,
a ocular hypertensiona
Treprostinil Prostacyclin agonist Peripheral vascular disorders, pulmonary fibrosis,
pulmonary arterial hypertension,a transplantation
Unoprostone Prostaglandin F2 alpha agonist Glaucoma,
a ocular hypertensiona
a Indication(s) approved by the United States Food and Drug Administration. Analogs with indications specific for PAH or pursuing
indications for PAH are bolded.
12 K.K. Mubarakalternatively spliced variants that may couple to different
G-proteins.
Prostacyclin and IP
Prostacyclin is produced by vascular endothelial cells18 and
inhibits vascular smooth muscle cell (VSMC) proliferation
and migration,19 with VSMC proliferation being a major
factor in the development of vascular disease. Prostacyclin
also plays an important role as an endogenous regulator of
vascular homeostasis, inhibits platelet aggregation, stimu-
lates VSMC relaxation, and regulates VSMC differentia-
tion.19 Prostacyclin also has cardioprotective effects during
ischemia-reperfusion injury20 and is also an important
mediator of acute inflammation and inflammatory pain
transmission.21,22
The IP receptor predominantly couples to the Gs type
protein leading to an increase in cAMP, which results in vas-
odilatory and anti-aggregatory effects (Table 3). The IPTable 2 Summary of prostaglandins and their physiologic roles
System Mediator(s) Major Site(s)
Cardiovascular Prostacyclin Endothelial ce
Thromboxane Platelets
Renal Prostacyclin Renal cortex
PGE2 Renal medulla
Gastrointestinal PGE2 Gastric mucos
Hematologic Prostacyclin Endothelial ce
Thromboxane Platelets
Respiratory Prostacyclin Endothelial ce
Musculoskeletal PGE2 Osteoblasts
Reproductive PGE2 Seminal vesic
PGE2, PGF2 Fetal membra
Uterus
Neurologic PGE2 Unknown
Reprinted from Semin Arthritis Rheum, Miller SB, Prostaglandins in he
from Elsevier.98
PGE2, prostaglandin E2; and PGF2, prostaglandin F2.receptor can also couple to other G-proteins due to C-
terminal modification (Gi and Gq).
23 The IP receptor is
thought to undergo agonist-induced desensitization in vivo,24
and agonist-induced internalization and sequestration inde-
pendently from desensitization.25 These processes may
affect the long-term effectiveness of prostaglandin analogs.
PGE2 and EP1e4
PGE2 is the most widely produced prostaglandin in the body
and exhibits the most versatile actions. It exerts both pro- and
anti-inflammatory effects depending on the receptor subtype,
cell population, and context of activation.26 Therefore, PGE2
may have either dilator or constrictor effects on vascular
smooth muscle.27,28
The many different physiological effects of PGE2 may be
accounted for in part by the existence of the four EP receptors
(EP1, EP2, EP3, and EP4) and heterogeneity in the coupling of
these receptors to intracellular signal transduction pathwaysin major organ systems.
of Synthesis Primary Effect(s)
lls Vasodilatation
Vasoconstriction
Vasodilatation
Salt and water excretion
a Cytoprotection
lls Platelet deaggregation
Platelet aggregation
lls Vasodilatation
Bone resorption,bone formation
les Erection, ejaculation, sperm transport
nes Parturition/labor, menstruation,
fertilization, ovulation
Fever, hyperalgesia
alth and disease: An overview, Copyright (2006), with permission
Table 3 Signal Transduction of Prostanoid Receptors.
Type Subtype Isoform G protein Second messenger
DP Gs cAMP [
EP EP1 Unidentified Ca
2þ [
EP2 Gs cAMP [
EP4 Gs cAMP [
EP3 EP3A Gi cAMP Y
EP3B Gs cAMP [
EP3C Gs cAMP [
EP3D Gi, Gs, Gq cAMP Y, cAMP [,
PI response
FP Gq cAMP [, PI response
IP Gs, Gq cAMP [, PI response
TP TPa Gq, Gi PI response, cAMP Y
TPb Gq, Gs PI response, cAMP [
Reproduced with permission from Narumiya S et al. Prostanoid
receptors: structures, properties, and functions. Physiol Rev.
1999;79:1193e1226.53
cAMP, cyclic adenosine monophosphate; PI, phosphatidylino
sitol; [Z increase; and YZ decrease.
Prostaglandins in PAH 13(Table 3). Of the four EP receptors, the EP3 and EP4 receptors
bind PGE2 with highest affinity (Kd< 1 nM), whereas the EP1
and EP2 receptors bind with lower affinity (Kd> 10 nM).
29
The EP3 receptor has multiple splice variants in its C-
terminal tail that cause differential activation of signal
transduction pathways.26 The EP2 receptor plays a role in
ovulation and fertilization, facilitates pain transmission by
abolishing glycinergic inhibition, and mediates joint inflam-
mation in collagen-induced arthritis.30 The EP4 receptor
facilitates closure of ductus arteriosus,31 induces bone
formation, mediates joint inflammation in collagen-induced
arthritis, protects against inflammatory bowel disease, and
facilitates Langerhans cell migration and maturation.30
PGD2 and DP
PGD2 is the predominant prostaglandin produced by acti-
vated mast cells, which initiate IgE-mediated type I acute
allergic responses.32 PGD2 may also exacerbate nonimmune
pathological processes associated with asthma, such as
airway remodeling and bronchoconstriction.26 The effects
of PGD2 result from binding to two different GPCRsdthe DP
receptor and the CRTH2 receptor, a seven-transmembrane,
G-protein coupled, chemoattractant receptor-homologous
molecule expressed on Th2 cells.
PGF2 and FP
Prostaglandin F2a is produced during the menstrual cycle by
secretory endometrium.33 Changes in PGF2a production
have been linked to abnormal menstrual bleeding.34 PGF2a
also affects renal function,35 cardiac hypertrophy,36 and
intraocular pressure.37 Selective FP agonists such as lata-
noprost have been approved by the US FDA for the treat-
ment of ocular hypertension.38 The FP receptor is the least
selective of the prostanoid receptors in binding the
endogenous prostaglandins, binding both PGD2 and PGE2 at
nanomolar concentrations.29Prostanoid receptors and the lung
In the lung, four different prostanoid receptors have been
identified that play a role in regulating vascular tone,
platelet activation, and immunological cell responses.
Vasoconstriction is produced by TX receptors via a signaling
pathway coupled with phospholipase C activation and Ca2þ
mobilization.39 EP3 receptors also produce vasoconstriction
through two different mechanisms: phosphoinositide me-
tabolism and Ca2þ release via Gq proteins and inhibition
of cAMP via Gi proteins.
40 The remaining two prostanoid
receptors, IP and EP2, increase plasma cAMP and have vaso-
dilatory effects. Activation of both receptors produces
increased intracellular cAMP levels, resulting in the opening
of Ca2þ-activated Kþ channels, cellular hyperpolarization,
and vasodilatation.41e43
The distribution of these various prostanoid receptors is
not homogeneous throughout the human pulmonary vascular
system. The IP receptor is expressed in smooth muscle cells
in pulmonary arteries and veins.43 On the other hand, EP2
receptors that mediate vasorelaxation are predominantly
expressed in pulmonary veins.44 These distribution differ-
ences may influence the results observed in clinical studies
for various prostaglandin analogs.Prostaglandin analogs and immunosuppression
Although clinical studies of infection and prostaglandin
analog use are few, there has been a growing body of
evidence to implicate immunosuppression in experimental
models of prostaglandin analog therapy. Treprostinil
inhibits human mixed lymphocyte culture responses similar
to cyclosporine,45 possibly via its agonism of the EP2
receptor.46 Phagocytosis of Micrococcus species can be
inhibited by prostaglandin analogs, possibly via their ago-
nism on the IP receptor.47 The differential effects of various
prostaglandin analogs (iloprost, carbaprostacyclin, and
treprostinil) on macrophage function in rats were recently
reported.46 In this in vitro study, the effects of the pros-
tacyclin analogs on the regulation of phagocytosis, bacte-
rial killing, and inflammatory mediator production were
determined in alveolar macrophage and peritoneal macro-
phage populations. Treprostinil inhibited phagocytosis,
bacterial killing, and cytokine generation in alveolar
macrophages to a much greater degree than the other two
prostaglandin analogs. Thus, there are differences in the
immunoregulatory properties of these prostaglandin
analogs, which may hold important consequences regarding
the risk of infection for patients receiving these drugs.
Furthermore, differences in receptor affinity may predis-
pose patients receiving chronic prostaglandin therapy to
heterogeneous varieties of immunosuppression.
Serious gram-negative bloodstream infections have
recently been observed in patients receiving chronic intra-
venous treprostinil.48,49 Similar bloodstream infections have
been noted with intravenous epoprostenol; however, those
have predominantly been of the gram-positive variety, in
particular Micrococcus species.50 Micrococcus infections
are usually only seen in immunocompromised hosts. Such
infections have not been noted with subcutaneous trepros-
tinil. These differences may be due to the higher dose of
14 K.K. Mubaraktreprostinil usually administered via the intravenous route or
to differences in catheter care and injection site (intrave-
nous versus subcutaneous). Nonetheless, the differences in
bacteriology suggest that there may be immune conse-
quences of chronic prostaglandin analog therapy. This view is
buttressed by reports of sepsis with analogs of prostaglandin
E1, including misoprostol
51 and alprostadil,52 even in the
absence of an intravenous catheter.
Prostacyclin and prostaglandin analogs
The vasodilatory effects of prostacyclin constitute the
major mechanism of action in PAH. Epoprostenol, a freeze-
dried synthetic preparation of prostacyclin, binds to the IP
receptor. Prostaglandin analogs have been produced by
various companies and these include iloprost, treprostinil,
and beraprost (Fig. 2). These analogs are available in
different formulations and have different binding affinities
for the various prostanoid receptors. Iloprost binds to the
IP, EP1, EP3 and EP4 receptors,
53,54 treprostinil binds to the
IP55 and EP2
46 receptors, and beraprost binds to the IP and
EP3 receptors (Fig. 3).
53 Activity of these analogs on other
prostanoid receptors remains unknown.
Epoprostenol
Epoprostenol must be administered by continuous intrave-
nous infusion because of its short half-life of 3e5 min and
its instability at pH values <10.5.56,57 Intravenous admin-
istration of the drug requires a permanently implantedFigure 2 Chemical structure of prostacyclin, epoprostenol, its
stable analogs, and a prostacyclin receptor agonist. 1ZMRE-269;
2aZNS-304. Reprinted from Pharmacol Ther, 102(2), Olschewski
H et al., Prostacyclin and its analogues in the treatment of
pulmonary hypertension, 15, Copyright (2004)43 and Bioorg Med
Chem, Nakamura A et al, Synthesis and evaluation of N-acylsulfo-
namideandN-acylsulfonylurea prodrugs of a prostacyclin receptor
agonist, Copyright (2007), with permission from Elsevier.89central venous catheter and a portable infusion pump, as
well as refrigeration of the drug in its high pH glycine buffer
during administration. An additional requirement is the fact
that the infusion has to be prepared every 24 h. Due to its
chemical instability, the pharmacokinetics of epoprostenol
are difficult to determine. Recently, a formulation of epo-
prostenol that uses a higher pH, and therefore affords
greater chemical stability, has become available.58 This
new formulation is stable for 24 h without refrigeration at
concentrations 15,000 ng/mL.
One of the clinical studies that led to US FDA approval of
epoprostenol for treatment of PAH was a 12-week prospec-
tive, randomized, multicenter, placebo-controlled, open
trial that compared the effects of intravenous epoprostenol
plus conventional therapy with those of conventional
therapy alone in 81 patients with severe PAH (New York
Heart Association [NYHA] class III or IV).59 Exercise capacity
(assessed by the 6-min walk distance [6MWD]) at 12 weeks
was improved in the 41 patients treated with epoprostenol,
but it decreased in the 40 patients treatedwith conventional
therapy alone (P< 0.002 for the comparison of the treat-
ment groups). Hemodynamics significantly improved at 12
weeks in the epoprostenol-treated patients (mean PAP,
P< 0.002; PVR, P< 0.001). Serious adverse events included
four episodes of catheter-related sepsis and one thrombotic
event. Eight deaths occurred during the study, all of whom
were receiving conventional therapy (PZ 0.003). Thus, the
continuous intravenous infusion of epoprostenol produced
symptomatic and hemodynamic improvement, as well as
improved survival in patients with severe PAH. In addition to
this study, several subsequent clinical trials have extensively
studied the safety profile of long-term administration of
epoprostenol.8,24,60e63
A randomized, open-label, controlled trial examined the
effects of treatment with epoprostenol in 111 patients with
PAH associated with scleroderma.64 Treatment with epo-
prostenol for 12 weeks improved exercise capacity (change
from baseline in median 6MWD, þ46 m) but decreased with
conventional therapy (change from baseline in median
6MWD, 48 m; P< 0.001). Improvement in NYHA functional
class only occurred in patients treated with epoprostenol
(NZ 21). There was no significant difference in mortality
between the two groups (epoprostenol, four deaths vs
conventional therapy, five deaths; P-value not significant).
Side effects of epoprostenol therapy included jaw pain,
nausea, and anorexia. Adverse events that were reported
and were related to the epoprostenol delivery system
included sepsis, cellulitis, hemorrhage, and pneumothorax
(4% for each).
Intravenous epoprostenol requires dose titration to
overcome tachyphylaxis. A typical patient may require
uptitration for 6 months to reach a dose up to 30e40 ng/kg/
min. The American College of Chest Physicians (ACCP) and
European Society of Cardiology (ESC) recommend IV epo-
prostenol in patients with NYHA functional class III and IV
(evidence: A).5,65 Systemic side effects related to the long-
term administration of epoprostenol include flushing,
warmth, headaches, photosensitivity, jaw pain, abdominal
pain, and diarrhea.66 There may be recurrent infections of
the intravenous catheter.60 Tolerance develops during long-
term use of the drug, leading to progressive increases in the
dose for several months after initiation.
Prostanoid Receptor Functional Characterization
cAMP Gene regulation
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Figure 3 Functional characterization of some of the prostanoid receptors, showing the binding characteristics of different pros-
taglandin analogs. AC, adenylate cyclase; ATP, adenosine triphosphate; cAMP, cyclic adenosine monophosphate; DAG, diacylglycerol;
IP3, inositol triphosphate; PIP2, phosphatidylinositol 4,5-biphosphate; PLC, phospholipase C; PKA, protein kinase A; PKC, protein kinase
C; SMC, smooth muscle cell.
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Iloprost is a carbacyclin analog of prostacyclin that has
a plasma half-life of 20e30 min. It is available in different
countries in intravenous or inhaled formulations. Inhaled
iloprost causes pulmonary vasodilation that lasts for 1e2 h67
and has been approved for the treatment of PAH in Australia,
Austria, France, Germany, Ireland, Israel, Italy, the
Netherlands, New Zealand, Norway, Switzerland, the United
Kingdom, and the USA. The intravenous formulation is
approved in New Zealand for PAH and is used elsewhere off-
label for PAH. Intravenous iloprost has received regulatory
approval in Europe for the treatment of thromboangiitis
obliterans.
The pharmacokinetics of a standardized iloprost aerosol
dose (5 mg; inhaledwithin approximately 10 min) was studied
in 12 patients with severe pulmonary hypertension (PH) in
a crossover design employing three different nebulizers (Ilo-
Neb/Aerotrap [Nebu-Tec; Elsenfeld, Germany], Ventstream
[Medic-Aid Limited; Bognor Regis, UK], and HaloLite [Profile
Therapeutics Ltd.; Bognor Regis, UK]).68 All three nebulizers
produced similar decreases in PVR and PAP. Iloprost entered
rapidly into the systemic circulation, with peak concentra-
tions occurring immediately after termination of the inha-
lation maneuver. The half-lives of serum levels of iloprost
ranged from 6.5 min to 9.4 min; however, the ‘‘half-life’’ of
the pharmacodynamic effects in the pulmonary vasculature
(i.e., decrease in PVR)was longer and ranged between 21 and
25 min. An in vitro study suggests that tolerance to iloprost
may develop rapidly.69 In perfused rabbit lungs, the pulmo-
nary vasodilatory response to aerosolized iloprost after
3e3.5 h had leveled off, whereas two-thirds of themaximum
iloprost perfusate levels were still present.One of the clinical studies that led to US FDA approval of
inhaled iloprost for the treatment of PAH was a 12-week,
randomized, placebo-controlled study in 203 patients with
severe PAH or chronic thromboembolic PH.70 The patients
received daily inhalations of 2.5 or 5.0 mg of iloprost (six
to nine times per day; median inhaled dose, 30 mg per day)
or inhalation of placebo. The primary endpoint consisted of
a composite endpoint of patient improvement where each
patient had to experience an increase of at least 10% in the
6MWD with an improvement in NYHA class by at least one
class in the absence of clinical deterioration or death. This
clinical response endpoint was met by 17% of the patients
receiving iloprost, as compared with 5% of the patients
receiving placebo (PZ 0.007). Hemodynamic values were
significantly improved at 12 weeks when measured after
iloprost inhalation (P< 0.001) and were significantly worse
in the placebo group. The most common adverse event was
flushing.
Combination therapy of inhaled iloprost with oral bosen-
tan has been studied in 67 patients with PAH.71 In a random-
ized, multicenter, double-blind trial, inhaled iloprost (5 mg)
or placebo was added to monotherapy with bosentan for 12
weeks. This was primarily a safety study, and secondary
efficacy endpoints included change from baseline in 6MWD,
NYHA functional class, hemodynamic parameters, and time
to clinical worsening. After 12 weeks, patients receiving ilo-
prost had a placebo-adjusted difference in 6MWD of þ26 m
(PZ 0.051). The NYHA status improved by one class in 34% of
iloprost versus 6% of placebo patients (PZ 0.002). Treatment
with iloprost significantly delayed the time to clinical wors-
ening (PZ 0.0219). Improvements were noted in post-
inhalation placebo-adjusted hemodynamics (mean PAP,
P< 0.001; PVR, P< 0.001). No significant adverse events
16 K.K. Mubarakwere reported. However, these data could not be replicated
in a similar study where patients on bosentan were random-
ized to inhaled iloprost versus placebo. The study was
terminated earlier because interim statistical analysis
demonstrated futility of outcome.72
Combination therapy of inhaled iloprost with oral silde-
nafil has also been studied. In a randomized, controlled,
open-label trial, 30 patients with severe PHwere assigned to
receive 12.5 mgof oral sildenafil, 50 mgof sildenafil, 12.5 mg
of sildenafil plus inhaled iloprost, or 50 mg of sildenafil plus
inhaled iloprost.73 The efficacy endpoints were hemody-
namic measurements (PAP, pulmonary arterial occlusion
pressure, cardiac output, central venous pressure). The rank
order of pulmonary vasodilatory potency (maximum reduc-
tion of PVR and increase in cardiac index) was the following:
50 mg of sildenafil plus iloprost> 12.5 mg of sildenafil plus
iloprost> iloprost alone, and 50 mg of sildenafil> 12.5 mg of
sildenafil and nitric oxide. No serious adverse events were
reported. The authors concluded that oral sildenafil acts
synergistically with inhaled iloprost to cause pulmonary
vasodilatation in severe PH.
The dose of inhaled iloprost is not uptitrated, perhaps
because intermittent low dose delivery does not engender
tachyphylaxis. The inhaled dose of approximately 0.37 ng/kg/
min is considerably lower than when iloprost is used intrave-
nously (off-label) for PAH at about 5 ng/kg/min. The ACCP and
ESC recommend inhaled iloprost in patients with NYHA func-
tional class III (ACCP evidence, A; ESC evidence, B) and func-
tional class IV (ACCP evidence, B; ESC evidence, C).5,65
Treprostinil
Treprostinil is a prostaglandin analog that is chemically
stable at room temperature and has a neutral pH. It has
a relatively long terminal half-life but a relatively short
effective half-life. It has been approved for the treatment of
PAH in Australia, Brazil, Canada, the European Union, Israel,
Switzerland, Taiwan, and theUSA. Subcutaneous formulation
of treprostinil was approved by the FDA in 2002. Subse-
quently, the same formulation was approved for intravenous
use based upon bioequivalence in normal volunteers, without
any patient study.
Several studies have examined the pharmacokinetics of
treprostinil. The bioequivalence of intravenous and subcu-
taneous administration of treprostinil to normal volunteers
has been studied using a randomized, two-period, crossover
study design.74 Each subject was dosed at 10 ng/kg/min for
72 h by each route, with the infusions separated by a 4-day
washout period. The steady-state ratios of the geometric
means (intravenous/subcutaneous) for the area under the
concentration-time curve and the maximum plasma
concentration indicate bioequivalence. The study also
showed that, at steady state, the elimination half-life of
treprostinil was 4.4 and 4.6 h following intravenous and
subcutaneous administration, respectively, but the effec-
tive half-life was less than 10 min and 60 min, respectively.
In another study conducted in 15 healthy volunteers, the
mean apparent elimination half-life of treprostinil (infused
at 15 ng/kg/min over 150 min) following subcutaneous
administration was 1.38 h, compared to 0.87 h following
intravenous administration.75 Finally, in another study, dose
proportionality was shown for treprostinil administered bycontinuous subcutaneous and intravenous infusion at doses
up to 125 ng/kg/min.76
A 12-week, double-blind, placebo-controlled multi-
center trial was conducted in 470 patients with PAH.77 The
primary endpoint was exercise capacity as given by the
6MWD. Exercise capacity improved with treprostinil and
was unchanged with placebo; the between-treatment
group difference in median 6MWD was þ16 m (PZ 0.006).
Treatment with treprostinil significantly improved indices
of dyspnea, signs and symptoms of PH, and hemodynamics.
The most common side effect attributed to treprostinil was
infusion site pain (85% versus 27% for placebo) leading to
premature discontinuation from the study in 8% of patients.
Infusion system malfunctions were common and occurred in
24% of the patients in the treprostinil group and in 33% of
the patients in the placebo group.
Pilot studies were conducted to evaluate the effects of
treprostinil for the management of PAH.78 In the first trial,
intravenous epoprostenol and intravenous treprostinil were
compared, with both treatments producing similar acute
decreases in PVR (22% and 20%, respectively). In the second
trial, intravenous and subcutaneous treprostinil were
compared, with both treatments demonstrating similar
decreases in PVR (23% and 28%, respectively). In the third 8-
week trial, a multicenter, double-blinded, parallel study,
subcutaneous treprostinil was compared with placebo
infusion in 26 patients. Two patients in the treprostinil
group (12%) withdrew from the study because of intolerable
side effects (hypotension and intolerable pain at the infu-
sion site). Although not statistically significant, the 6MWD
demonstrated a mean improvement of 37 m in patients
receiving treprostinil compared with a 6-m reduction in
those receiving placebo. Treatment with treprostinil had
favorable effects on 6MWD and hemodynamics; however,
the differences were not statistically significant. Adverse
effects reported included headache, diarrhea, flushing, jaw
pain, and foot pain. Injection site reactions, such as
erythema (94%) and pain (88%), were frequently observed
with subcutaneous treprostinil.
The typical dose of treprostinil when used subcutane-
ously or intravenously varies from 50 to 100 ng/kg/min. An
inhaled dose of 45 mg four times a day equals approximately
1.8 ng/kg/min. The ACCP recommends SC and IV trepros-
tinil in patients with NYHA functional class II (evidence: C
and C, respectively), functional class III (evidence: B and C,
respectively), and functional class IV (evidence: C and C,
respectively)5 whereas the ESC has equal recommendations
for SC and IV treprostinil in patients with NYHA functional
class III and IV (evidence: B).65
Transitioning long-term epoprostenol patients to IV or SC
treprostinil has been investigated. It has been shown that
both pediatric and adult patients with PAH who have
received IV epoprostenol long-term can be successfully
transitioned to IV or SC treprostinil.79e82 This transition can
be rapid (over 24e48 h) or slow (up to 14 days). The safety
profile of long-term treprostinil has been shown to be
consistent with short-term treprostinil treatment,83 and the
side effects are reported to be much less than those with
epoprostenol.79e83
Inhaled treprostinil is currently being studied in the
TReprostinil Sodium Inhalation Used in the Management
of Pulmonary Arterial Hypertension trial (TRIUMPH-1).
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double-blind, randomized, placebo-controlled study in
235 NYHA class III and IV patients with PAH were recently
reported in abstract format.84 Treprostinil (up to 45 mg
four times daily) or placebo was inhaled, and the primary
endpoint was the change at 12 weeks from baseline in the
6MWD. The peak (10e60 min after inhalation) median
change in 6MWD was þ20 m compared with placebo
(P< 0.006) and the placebo-subtracted trough (>4 h after
inhalation) change was þ14 m. However, there was no
improvement in time to clinical worsening or functional
class. A serum biomarker, B-type natriuretic peptide, was
significantly decreased indicating improvement in right
ventricular stretch.
A sustained-release formulation of oral treprostinil is
currently under investigation in phase III trials. Results of
the FREEDOM-C trial (combination therapy with sildenafil or
bosentan) were recently released.85 The improvement in
6MWD was only 11 m and did not reach statistical signifi-
cance. Results of the FREEDOM-M trial (monotherapy) have
yet to be reported.
Beraprost
Beraprost is an orally administered prostaglandin analog
with a half-life in healthy adults of 0.9 to 1.1 h.57 It has
been approved for the treatment of PAH in Japan and South
Korea, and phase II studies of a sustained-release formu-
lation are being conducted in the US.
The pharmacokinetics and pharmacodynamics (inhibi-
tion of platelet aggregation) of oral beraprost were studied
in 12 healthy volunteers in a double-blind, placebo-
controlled, dose-escalating crossover study.86 Beraprost
(20, 40, 60 mg) and placebo were administered acutely and
repeated three times daily for 3 days. Inhibition of platelet
aggregation occurred 1 h after single doses and 0.5e1.0 h
after repeated doses for the 40 and 60 mg doses. The
terminal half-life of the active enantiomer of beraprost
ranged from 0.50 to 0.91 h. The side effects reported were
moderate headaches (7 of 12 after single and 8 of 12 after
repeated doses) and flushes (6 of 12 and 7 of 12,
respectively).
In a double-blind, placebo-controlled study, 130 patients
with PAH were randomized to oral beraprost (median dose
80 mg four times a day) or to placebo for 12 weeks.87 The
primary endpoint was the change in 6MWD, and secondary
endpoints included changes in hemodynamics and NYHA
functional class. The difference between treatment groups
in the mean change of 6MWD at Week 12 was þ25 m
(PZ 0.036). Improvement in 6MWD only occurred for
patients with idiopathic PAH and not PAH associated with
different conditions. There were no statistically significant
changes in cardiopulmonary hemodynamics or NYHA func-
tional class. Drug-related adverse events, such as head-
ache, flushing, jaw pain, and diarrhea, were more common
in the titration phase and decreased in the maintenance
period.
In a 12-month double-blind, randomized, placebo-
controlled study, a total of 116 patients with World Health
Organization functional class II or III idiopathic PAH or PAH
related to either collagen vascular diseases or congenitalsystemic to pulmonary shunts received either oral bera-
prost (median dose 120 mg four times a day) or placebo.88
The primary endpoint was disease progression (defined as
death, transplantation, epoprostenol rescue, or a> 25%
decrease in peak oxygen consumption). Patients treated
with beraprost exhibited significantly less disease
progression at 6 months (PZ 0.002), but not at shorter or
longer follow-up intervals. Similarly, beraprost-treated
patients had significantly improved 6MWD at 3 months and
at 6 months (PZ 0.010 and 0.016, respectively) compared
with placebo, but not at either 9 or 12 months. Drug-
related adverse events were common and were related to
the disease or to expected prostacyclin adverse events.
These results suggest that treatment with beraprost may
produce beneficial effects early but that this effect is not
sustained.
NS-304/ACT-293987
NS-304/ACT-293987 is a prostacyclin receptor agonist that
is chemically dissimilar from prostanoids. It is a pro-drug
that has low affinity for the IP receptor natively, but is
metabolized in hepatic microsomes to MRE-269, which
selectively binds the IP receptor. By this metabolic step,
the native compound avoids causing gastrointestinal side
effects when given orally, and leads to sustained release of
MRE-269 with a longer half-life.89
Preclinical studies of MRE-269 in rats, dogs, and monkeys
showed that the compound displayed high oral bioavail-
ability (rat, 102%; dog, 80%) and a long half-life (rat, 3.6 h;
dog, 6.2 h; monkey, 5.6 h).90 MRE-269 has a 130-fold higher
affinity for the IP receptor than for the other human pros-
tanoid receptors.4 NS-304/ACT-293987 is also highly selec-
tive for the IP receptor and produces no significant IP
receptor desensitization.4 Finally, a microdose study of oral
NS-304/ACT-293987 (100 mg) conducted in five healthy
volunteers showed that it was metabolized to MRE-269 in
the human body with an elimination half-life of 7.9 h. The
only adverse events reported that were thought to be
related to the study drug were two headaches that were
mild in intensity. In a comparison with oral beraprost, these
studies conducted in rats, dogs, and monkeys showed that
NS-304/ACT-293987 was superior to beraprost in efficacy,
persistence in the blood plasma, and overall safety
margin.4
NS-304/ACT-293987 showed efficacy in a preclinical
study conducted in monocrotaline-induced PH in rats.91
Treatment with NS-304/ACT-293987 results in improved
vascular endothelial function, reduced pulmonary arterial
wall hypertrophy, decreased right ventricular systolic
pressure, and improved survival. In summary, NS-304/ACT-
293987 has characteristics that make it a promising candi-
date for ideal oral combination therapy in patients with
PAH utilizing drugs that target the three major pathways
(prostacyclin, nitric oxide, and endothelin-1).
Discussion
This review indicates that there are significant differences
among the various prostaglandin analogs. For example, the
prostaglandin analogs have different binding affinities for the
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prostaglandin receptors involved in VSMC relaxation; however,
less is known about the binding affinities of the other analogs.
The different binding affinities and different GPCR coupling
interactions for the various prostaglandin analogsmay result in
different clinical efficacies or safety, depending on the target
tissue.56 The various different prostaglandin analogs have
different pharmacokinetics, which may also impact their
effectiveness, safety, or ease of use. Head-to-head studieswill
be needed to confirm implied differences in efficacy or safety.
A small number of preclinical studies have directly
compared the effects of several prostaglandin analogs on
different physiological systems. One study examined the
effects of iloprost, treprostinil, and beraprost on smooth
muscle proliferation and cAMP generation in the human
pulmonary artery.55 Serum-induced proliferation produced
by a number of prostacyclin analogs acting on pulmonary
artery smooth muscle cells was assessed by either
counting the cell number or measuring [3H]thymidine
incorporation. The ranking in effectiveness in decreasing
proliferation by 1 mM concentrations was treprosti-
nil> iloprost> cicaprost> beraprost; however, the EC50
values for the first three analogs are not significantly
different from each other (EC50Z 8.2 nM, EC50Z 4.8 nM,
EC50Z 7.1 nM, and EC50Z 98.2 nM, respectively). Intra-
cellular cAMP was elevated by all analogs, with trepros-
tinil producing a significantly larger and more sustained
increase compared with other analogs and with iloprost
producing the smallest increase. However, whether these
in vitro differences in effectiveness would translate into
differences in clinical effectiveness is not known.
The route of administration may be important in deciding
upon a particular prostaglandin analog for an individual
patient. Intravenous administration requires an ambulatory
infusion pump with a central venous catheter, with their
attendant risks of sepsis, thrombosis, catheter disruption, and
pump failure. Interruption of the infusion or underdosing of
prostacyclin and prostaglandin analogs may induce the acute
return of PAH symptoms that can be life-threatening.66,92
Additionally, the high cost of long-term prostacyclin therapy
(cost of the drug, the ambulatory pump, and intravenous lines
and supplies) and subsequent need for health insurance for
lung transplantation must also be considered.66
Subcutaneous administration eliminates the need for
venous access. The intravenous formulation of treprostinil is
associated with more prominent side effects (headaches and
leg pain) than the subcutaneous formulation, perhaps because
of a higher dose.93 However, continuous subcutaneous infusion
of treprostinil is painful, with the drug causing erythema,
induration, and sometimes ulceration of the skin.77
Inhaled administration of the prostaglandin analogs
decreases the risk of systemic side effects by delivering the
drug directly to the alveolar capillaries. However, the dose
delivered is a fraction of the dose delivered intravenously,
perhaps explaining lesser improvement in 6MWD compared
to subcutaneous or intravenous delivery. Iloprost is inten-
ded to be delivered in the US by either of two different
nebulizer systems (I-Neb Adaptive Aerosol Delivery
[AAD] System [Respironics, Inc.; Murrysville, PA, USA] or
the Prodose AAD System [Profile Therapeutics, Ltd.;
Bognor Regis, UK] [no longer being manufactured]). These
specific nebulizers use AAD to analyze the patient’sbreathing pattern in order to specifically deliver the aerosol
during inhalation. This technology reduces the variability in
the delivered dose, and reduces the waste of aerosol to the
environment during exhalation.94 Delivery of the required
dosage of iloprost takes approximately 10 min, depending
on the patients’ breathing patterns, six to nine times a day.
Therefore reducing the duration of daily inhalations would
be advantageous. Consequently, ongoing clinical trials are
evaluating the more rapid delivery of inhaled iloprost.
An oral formulation would have the advantage of being
more convenient than either continuous intravenous or
subcutaneous infusion or frequent time-consuming inhala-
tions. Oral formulations of treprostinil (FREEDOM clinical
trials) andNS-304/ACT-293987 are currently in development.
In addition to route of administration, pharmacoeconomic
considerations, including formulary status, are increasingly
affecting choice of PAH treatment. On the whole, few rigorous
pharmacoeconomic studies have been conducted on prosta-
cyclin-basedPAHtreatments, inpartdue to the recent increase
in available therapies. Among pharmacoeconomic studies that
investigated epoprostenol and treprostinil, results have been
mixed. A one-year study of treprostinil plus bosentan vs. epo-
prostenol indicated that treprostinil was more expensive than
epoprostenol with little improvement in quality-adjusted life
years.95 The increased dosing of IV treprostinil vs epoprostenol
(approximately 2 epoprostenol dosing) suggests that despite
similar efficacy and safety, IV treprostinil will be more expen-
sive than epoprostenol.96 However, another study that inves-
tigated epoprostenol and treprostinil over a three-year period
suggested that SC treprostinil was cheaper than epoprostenol
due to decreased sepsis.97
In summary, prostacyclin has many desirable effects on
the pulmonary vasculature that make it effective in the
treatment of PAH. Prostaglandin analogs are more chemically
stable than endogenous or synthetic prostacyclin, and are
approved by the FDA for the treatment of PAH. Differences in
formulation, route of administration, effectiveness, and
safety may all play a role in deciding on the specific prosta-
glandin analog to prescribe for an individual patient. Head-to-
head studies will be needed to confirm possible differences in
efficacy or safety for the various prostaglandin analogs.
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